-

ICON PUBLIC LIMITED COMPANY INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ:ICLR). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On February 12, 2026, ICON disclosed that its Audit Committee is conducting an investigation into certain accounting practices and internal controls, including revenue recognition practices during fiscal years 2023 through 2025. The Company stated that it expects to report one or more material weaknesses in internal control over financial reporting, has delayed the release of its fourth quarter and full year 2025 financial results, and has withdrawn its previously issued 2025 guidance. On this news, the price of ICON shares declined by $53.06 per share, or approximately 40%, from $133.14 per share on February 11, 2026 to close at $80.08 on February 11, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired ICON securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:ICLR

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

LCID INVESTOR REMINDER: Lucid Group, Inc. Investors Have Until July 28, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until July 28, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. Th...

INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) securities during the period of January 14, 2025 through April 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Erasca investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...

INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).If you suffered a loss on your ADMA investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...
Back to Newsroom